alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still no news about Pfizer's second generation Covid 19 drug. The primary completion date for the phase 2 trial was Sept 13 2023 and the actual completion date was Oct 11th.
https://clinicaltrials.gov/study/NCT05799495?term=PF-07817883&rank=5
https://clinicaltrials.gov/study/NCT05799495?term=PF-07817883&rank=5
Why are you repeatedly posting this garbage!
Thanks! I appreciate it. IMGN was my largest holding before today so you can imagine how happy today made me. IMGN is now 60% of my biotech portfolio from just under 40%. Some might say that is too high but it happened to me twice before, once when ONXX was bought out and again when TRIL was bought out.
With this all cash buyout I am going to have to find some new stocks to invest in.
If you notice, Paxton is lying when he said more people died in areas with higher vaccination rate, which is the opposite of
The reality. I thought Paxton is under investigation for fraud or some other serious crime so he is likely trying to deflect attention
Paxton is a full blown nut-job but the good people of Texas put him into office. Pretty sad.
What a great way to wake up in the morning!! 😀 Looks like Santa Claus came early for IMGN investors. While I am obviously very pleased with the big jump in IMGN stock price today, I think $10 billion is a bit lower than I was hoping for.
https://finance.yahoo.com/news/abbvie-acquire-immunogen-including-flagship-123000719.html
I haven't followed the CAR-T field so am unfamiliar as to how the generate the chimeric cells. Are they using CRISPR to generate the CAR-T cells?
Easy come, easy go as ENTA gives back most of yesterday’s gains.
Obviously Luly and ENTA know more about running a company than I do. I suggested the possibility of ENTA funding EDP-235 phase 3 Covid trials if a partner wasn't found as a signal of their faith in EDP-235. Instead, Luly and ENTA reduced research expenses to prolong the cash runway until 2027, which propelled the stock price higher today. Being wrong never felt so good. :). Kudos to dewophile for stain he was pleased that cash burn has been reduced.
I was pleased to hear that ENTA referenced their patent infringement lawsuit against PFE. Winning that lawsuit would be major price driver for ENTA.
Yes, Foley could have laid out the strategy for the CD launch after Daxxify was approved for that indication. It would have provided a rationale for the delay in CD launch as opposed to leaving the impression that Foley was clueless and caught flatfooted by approval.
The market jumped so much this morning that even ENTA is up. Will wonders never cease!